Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health, Sesame Partner on COVID-19 Test-to-Treat Program

NEW YORK – Telehealth firm Sesame and Lucira Health announced on Thursday that they are partnering to provide COVID-19 test-to-treat services. 

Under the partnership, people who purchase Lucira's molecular COVID-19 test will be able to access telehealth consultations from Sesame and, if necessary, learn about treatment options and receive a prescription from the visit for $29, the price of Lucira's test. The consultation is offered via Lucira Connect, the firm's web-based virtual care platform. 

Results from Lucira's self-administered test are provided in less than 30 minutes, and if the test is positive users have the option to book a consultation with a Sesame healthcare provider, the companies said in a statement. 

"The Lucira Connect test-to-treat platform enables unlimited, simultaneous rapid testing along with a treatment solution allowing individuals to take action and get on the path to recovery fast," Lucira Health President and CEO Erik Engelson said in a statement. "As Lucira rolls out additional tests, Lucira Connect and Sesame will serve as critical companions for users of our tests and partners to help in their care journey."

Emeryville, California-based Lucira received Emergency Use Authorization from the US Food and Drug Administration for its COVID-19 test in 2020 and for its COVID-19/influenza combination test in November.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.